Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042571 (
vertigo
)
7,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
History An 11-year-old boy taking oral antibiotics for
Fusobacterium
meningitis diagnosed 3 months earlier presented to the emergency department with a 1-week history of intermittent emesis, dizziness, and
vertigo
and a 1-day history of wobbly gait and bilateral lower extremity paresthesia without confusion. His metabolic profile was normal. Contrast material-enhanced MRI of the brain was performed, and selected images are shown ( Fig 1 - 4 ). Figure 1a:
(a)
Axial fluid-attenuated inversion recovery (repetition time msec/echo time msec, 11 000/125) MRI and
(b)
axial turbo spin-echo T2-weighted (3000/80) MRI of the brain through the cerebellum at presentation.
(c)
Axial fluid-attenuated inversion recovery (6000/120) MRI and
(d)
axial turbo spin-echo T2-weighted (5545/100) MRI through the same level of the cerebellum obtained 6 weeks earlier. Figure 1b:
(a)
Axial fluid-attenuated inversion recovery (repetition time msec/echo time msec, 11 000/125) MRI and
(b)
axial turbo spin-echo T2-weighted (3000/80) MRI of the brain through the cerebellum at presentation.
(c)
Axial fluid-attenuated inversion recovery (6000/120) MRI and
(d)
axial turbo spin-echo T2-weighted (5545/100) MRI through the same level of the cerebellum obtained 6 weeks earlier. Figure 1c:
(a)
Axial fluid-attenuated inversion recovery (repetition time msec/echo time msec, 11 000/125) MRI and
(b)
axial turbo spin-echo T2-weighted (3000/80) MRI of the brain through the cerebellum at presentation.
(c)
Axial fluid-attenuated inversion recovery (6000/120) MRI and
(d)
axial turbo spin-echo T2-weighted (5545/100) MRI through the same level of the cerebellum obtained 6 weeks earlier. Figure 1d:
(a)
Axial fluid-attenuated inversion recovery (repetition time msec/echo time msec, 11 000/125) MRI and
(b)
axial turbo spin-echo T2-weighted (3000/80) MRI of the brain through the cerebellum at presentation.
(c)
Axial fluid-attenuated inversion recovery (6000/120) MRI and
(d)
axial turbo spin-echo T2-weighted (5545/100) MRI through the same level of the cerebellum obtained 6 weeks earlier. Figure 2a:
(a)
Axial fast spin-echo T1-weighted MRI (496/8) and
(b)
axial reconstruction of three-dimensional fast field-echo T1-weighted contrast-enhanced (7 mL of gadobutrol, Gadavist;
Bayer
Healthcare Pharmaceuticals, Berlin, Germany) MRI (7.98/3.72) of regions similar to those in Figure 1 . Figure 2b:
(a)
Axial fast spin-echo T1-weighted MRI (496/8) and
(b)
axial reconstruction of three-dimensional fast field-echo T1-weighted contrast-enhanced (7 mL of gadobutrol, Gadavist;
Bayer
Healthcare Pharmaceuticals, Berlin, Germany) MRI (7.98/3.72) of regions similar to those in Figure 1 . Figure 3a:
(a)
Axial diffusion-weighted MRI (3090/71) and
(b)
axial apparent diffusion coefficient map (3090/71) of regions similar to those in Figure 1 . Figure 3b:
(a)
Axial diffusion-weighted MRI (3090/71) and
(b)
axial apparent diffusion coefficient map (3090/71) of regions similar to those in Figure 1 . Figure 4: Three-dimensional maximum intensity projection image (25/3.45) of the posterior cerebral circulation obtained with MR angiography of the head.
...
PMID:Case 271. 3121 57